Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT03635021 |
Title | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE) |
Recruitment | Recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
Indications | |
Therapies |
Fluorouracil + Irinotecan + Leucovorin + Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin |
Age Groups: | adult | senior |
Covered Countries | ESP |